Disc Medicine presents initial data from RALLY-MF Phase 2 trial of DISC-0974

Disc Medicin presented positive initial data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASH Annual Meeting in Orlando, FL. Initial results demonstrated: Consistent, substantial decreases in hepcidin reaching greater than75% reduction from baseline and corresponding increases in serum iron; 63% of baseline nTD patients achieved a hemoglobin increase of greater than or equal to1 g/dL for greater than or equal to12 weeks and 50% had an increase of greater than or equal to1.5 g/dL for greater than or equal to12 weeks; 71% of TD Low patients achieved transfusion independence over a 16-week period; 67% of TD High patients with at least 85 days on study achieved a greater than or equal to50% reduction in transfusion requirement; Initial data for additional n=3 TD High patients trending towards major response of TI greater than12 weeks; 50% of patients receiving concomitant JAK inhibitor therapy achieved a major hematologic response; Dosing with DISC-0974 was associated with improvements in FACIT-Fatigue scores in nTD and TD Low participants; DISC-0974 was generally well-tolerated. Diarrhea and urinary tract infections, neither considered serious, were the only adverse events that were considered related to DISC-0974 and reported in two or more subjects. The majority of AEs were not considered related to DISC-0974.